Recommendations developed for management of hidradenitis suppurativa
Evidence-based recommendations are presented for the management of hidradenitis suppurativa (HS) in guidelines of care issued by the American Academy of Dermatology and the Hidradenitis Suppurativa Foundation and published online Oct. 20 in the Journal of the American Academy of Dermatology.
Hidradenitis suppurativa (HS) management guidelines have been developed by the American Academy of Dermatology and the Hidradenitis Suppurativa Foundation. The guidelines provide 37 evidence-based recommendations for treating HS. Strongly recommended interventions include adalimumab, bimekizumab, infliximab, secukinumab, and routine pain assessment.
Conditional recommendations involve using topical therapies like clindamycin, resorcinol, and ruxolitinib, as well as systemic antibiotics such as oral doxycycline, tetracycline, clindamycin with rifampin, and intravenous ertapenem. Hormone therapy with spironolactone, short-term systemic corticosteroids, and upadacitinib are also conditionally recommended.
Specific procedural interventions, tobacco cessation, supportive pain management, zinc supplementation, and vitamin D repletion are conditionally suggested as well. These guidelines establish an evidence-based standard of care for HS, ensuring patients, dermatologists, and payers have a shared roadmap for high-quality HS care.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
